There is a growing demand across the UK for telemonitoring provided by Luscii. To steer expansion on the British side of the Channel in the right direction, Rob Brougham will be joining the team. He will begin his role as Managing Director for the United Kingdom on the 1st of May.
Impact on healthcare
Rob is a successful entrepreneur, and has also worked for large companies including British Telecom (BT) where he became CEO of the e-health division. The division built on the Whole Systems Demonstrator; a global, randomised controlled trial studying various tele-health systems. The positive impact of modern technology on the lives of patients with a chronic illness made a big impression on Rob. The number of hospital admissions (14-20%) and visits to emergency care (15%) were reduced significantly within the study population.
“Selling networks and systems to businesses is challenging”, Rob explains his decision, “but it doesn’t provide the same satisfaction that telemonitoring offers. Making a difference to people in a difficult situation is an important incentive for me”.
When BT shifted its strategic course and ventured away from tele-health, Rob decided to switch definitively to the e-health industry. First, as an advisor to various English e-health companies. Later, as UK Managing Director of Ieso Digital Health, which is one of the top 50 fastest growing e-health companies in the country. And, from the 1st of May onwards, as Managing Director for Luscii UK.
Rob sees plenty of opportunities for Luscii in the UK. “There are some players on the market, but we haven’t seen the levels of quality and accessibility of Luscii here, as yet”.
At any rate, Rob is set for a busy summer ahead. A number of British hospitals are about to start working with Luscii, while others are eager to discuss the possibilities that Luscii offers. The ambitions of Luscii are therefore perfectly in line with the “Long term plan”, presented in the past quarter by the NHS. Just like the Netherlands, the United Kingdom is struggling with increasing demand and staff shortages within the healthcare sector.
Now that Rob Brougham has been brought in to strengthen the UK division, many British patients and healthcare professionals will experience Luscii’s telemonitoring in the near future. We have faith that Rob will keep enough time free for his wife and daughters. Likewise, his five a side football team and waterskiing club won’t accept too many absences either!
Joining forces supports hospitals in moving care towards the home
Luscii, the e-health application for remote monitoring once developed as part of FocusCura, continues as an independent company. Healthcare entrepreneur and FocusCura founder Daan Dohmen, has acquired the majority of the shares and formed a strategic partnership with Omron Healthcare, known among other things, as the largest manufacturer of blood pressure monitors in the world. Part of this cooperation includes an investment, with which Luscii can accelerate its development further in the coming years. Omron will also support launches in more European countries, as the two companies announced today.
In European countries, efforts have been made for some time to make e-health available for chronic patients in order to prevent hospital visits and admissions. Despite that, a breakthrough is yet to be achieved. However, Luscii is one of the first digital healthcare concepts capable of bridging the important barriers in implementation. For example, Luscii successfully managed to integrate with large electronic patient records and secured reimbursement from insurers for their concept. Scientific research showed that using Luscii for specific target groups, such as patients with COPD, heart failure and resistant hypertension, can reduce hospital costs significantly and make patients feel safer.
FocusCura will continu its activities in home care under CEO Raoul Zaal. Dohmen handed over the CEO’s baton to the former Booking.com and Essent director a year ago. Under Zaal’s management, the number of users of FocusCura innovations continued to grow and 2018 ended with a strong operating result. Dohmen remains involved as a consultant and shareholder of FocusCura. Just like Medux, known for it’s brands Medipoint and Harting-bank.
Today there is good news for thousands of Dutch heart patients. After the largest insurer Zilveren Kruis announced to fully reimburse the e-health service HeartGuard, four other major healthcare insurers (VGZ, DSW, ONVZ, De Friesland) will also follow and reimburse HeartGuard in 2017. Cardiology Centers The Netherlands (CCN), together with Luscii, founding partner of HeartGuard, announced this news today.
HeartGuard enables continuous monitoring of cardiovascular patients suffering from heart failure, hypertension or atrial fibrillation. Patients can measure their vital signs at home with the Vitals App (formerly cVitals), developed by the Dutch healthcare innovation company Luscii.
The vital signs, like blood pressure or weight, are sent in remotely through the Vitals App on the patient’s iPhone or iPad to the cardiology centres and are automatically added to the Electronic Medical Record of the patient. Doctors and nurses will be alerted in case of detection of an increased health risk. Following that alarm, the staff will reach out to the patient and/or general practitioner. Hospital admissions and outpatient clinic visits are reduced by the HeartGuard service.
Fast scale up possible because of reimbursement
”Contracting with any of these four insurances companies makes it possible to offer the service to thousands of patients”, according to Cecile Goldman, VP of Operations at CCN. ”Now we can offer the service to patients insured at these insurers as well. This number can grow even further, when insurers CZ and Menzis will start reimbursing HeartGuard too. ”We are in dialogue with them to offer HeartGuard as well”.
CCN: “Dutch insurers are setting an example”
By reimbursing HeartGuard, Dutch insurers are setting an example. They are showing that they are not only retaining traditional care delivery, but are willing to support innovation. ”HeartGuard is at the forefront of further evolution in healthcare and by opening up the service to these new patients, we can increase our insights into the effects of this innovative healthcare service on an even larger scale”, says Cecile Goldman.
Insurer ONVZ: “enthusiastic about possibilities of eHealth”
Chairman of the Board of insurer ONVZ Jean-Paul van Haarlem is enthusiastic about the possibilities of HeartGuard for its clients: ”This is an innovation that provides patients with personalised care. HeartGuard will have a positive impact on quality of care and on efficient use of resources. Because it monitors the patient’s health remotely, HeartGuard will lead to a reduced number of hospital visits. This is a major improvement for the patient. Reimbursing HeartGuard is an important step for heart patients insured at ONVZ.
Insurer Zilveren Kruis: “good that others are following”
“We are very happy with the fact that we have realised this breakthrough last summer with Luscii and CCN to bring chronic cardiovascular care close to our clients. The fact that others follow this example towards innovative care, making it available to more patients is great”, says Erik-Jan Wilhelm, VP of Strategy and Innovation of Zilveren Kruis.
Dutch Patients Federation: “positive development”
The Dutch Patient Federation is happy that more and more insurers reimburse eHealth. ”We are glad that other insurers are following the example of Zilveren Kruis”, says Director Dianda Veldman. ”I hope more of these eHealth initiatives will be developed so all patients can enjoy this modern form of healthcare.”
Collaboration with hospitals and GPs
At this moment, only patients of Cardiology Centers the Netherlands are eligible to use HeartGuard, but, according to Cecile Goldman, this will change soon: ”We are already having conversations with GPs and hospitals to offer HeartGuard from their own locations to their own patients. We will monitor the patients in that case in commission of their own doctor. Scale is an important factor to eHealth, sharing our resources and expertise reduces the need for every hospital to reinvent the wheel“.
The role of Luscii in HeartGuard:
Luscii provides hardware, software and patient support in HeartGuard. As a spin-out brand of FocusCura, Luscii is co-initiator of the HeartGuard service, together with Cardiologist Center the Netherlands and insurer Zilveren Kruis. These three partners joined in a mutual innovation team to create the HeartGuard service. The Luscii platform is embedded as a button inside the EMR of the cardiologist (CardioPortal). Patients can download the Luscii Vitals and Luscii Contact apps on their iPhone or iPad, send in their measurements and have (video)-communication with the nurses or cardiologists. Also, after enrolment, Luscii is responsible for all logistics (sending the measurement devices), service and (installation) support for patients within HeartGuard.
This press release was published by Cardiology Centers The Netherlands and Luscii (previously FocusCura) on 6th March 2017.